Jim Tananbaum (Foresite Capital)
Foresite's Jim Tananbaum yanks $250M SPAC, as an RA-backed Oxford spinout braves the choppy IPO waters
The biotech market conditions have apparently gotten choppy enough to now preclude SPAC directors from taking their blank check companies public.
Jim Tananbaum’s Foresite Capital …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
